DexCom (DXCM) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.08 per share a year ago.

2 Growth Stocks That Could Double in 5 Years

10:23am, Thursday, 27'th Apr 2023
Vertex Pharmaceuticals will significantly expand its lineup over the next five years. DexCom's continuous glucose monitoring system should have a long growth runway.

2 Monster Stocks to Buy Without Any Hesitation

10:20am, Tuesday, 25'th Apr 2023
Eli Lilly's shares are up more than 235% over the past five years. Mounjaro is expected to be a blockbuster drug for Lilly.

Sell the News? 5 Reasons Tech May Pullback

02:28pm, Monday, 24'th Apr 2023
Though the medium-term trend remains intact for tech, some subtle signs of weakness are appearing beneath the surface. Andrew Rocco breaks it down.
Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.
Markets have been known to have periods of "nasty" industry group rotation. Get ahead of the curve with these 3 under-the-radar groups.
Here is how DexCom (DXCM) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Dexcom stock closed in on a breakout Monday after Medicare officials announced the biggest-ever expansion for coverage of CGMs in the U.S. The post The Medicare Decision That Propelled Dexcom Stock Cl
The healthcare sector has been looking fit in the past month, with medical products makers Stryker Corp. (NYSE: SYK) and Boston Scientific Corp. (NYSE: BSX) rallying to all-time highs, while sector pe
Analysts expect earnings to increase 22% this year and 38% in 2024. The post DexCom Stock Sets Up; Can It Catch Up To Company's Torrid Growth?
DexCom and Tesla have become profitable in recent years as their sales have soared. The two are focused on growing industries -- diabetes care and electric vehicles.
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
History shows that patient investors can reap rewards by consistently putting money to work. DexCom controls a notable slice of the diabetes care industry and is raking in profits.
Edwards Lifesciences' state-of-the-art heart valves have a big growth runway. Abbott Laboratories has received several encouraging FDA approvals recently.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE